
	Mr. John P. Schmid has been the Chief Financial Officer of Auspex Pharmaceuticals, Inc. since October 17, 2013. Mr. Schmid has over 20 years of experience in financial and senior management positions. He founded Trius Therapeutics, Inc. (formerly, Rx3 Pharmaceuticals Inc.) and served as its Chief Financial Officer since June 2004 until 2013. Mr. Schmid served as a Secretary of Trius Therapeutics, Inc. until 2013. He served as Chief Financial Officer of Vessix Vascular, Inc. He served as Principal Accounting Officer of Trius Therapeutics, Inc. He served as the Chief Financial Officer of Cengent Therapeutics, the successor company to GeneFormatics Inc., which he co-founded with scientists from The Scripps Research Institute. He served as Chief Financial Officer of GeneFormatics Inc. He served as Chief Financial Officer of Endonetics Inc., (acquired by Medtronic, formerly, Akos Biomedical). He served as President of the San Diego Venture Group. He served as Financial analyst for J.P. Morgan. He served as Associate with Idanta Partners, a San Diego-based venture capital firm. Before Idanta, he served as Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover in New York. He serves as board member of the San Diego Venture Group. Mr. Schmid received a B.A. in economics from Wesleyan University and an M.B.A. from the University of San Diego.
